NCT01050829已完成3 期
A Multi-center/Multi-national, Randomized, Controlled, Single-blind, Group Comparison Phase 3 Study to Determine the Efficacy and Safety of Gadobutrol 1.0 Molar in Comparison to Magnevist Following Single Injection in Patients Referred for Contrast-enhanced MRI of the Body/Extremities Regions (Breast, Heart, Abdomen, Kidney, Pelvis, or Extremities)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 370
- 主要终点
- The total score of the following 3 visualization parameters is used for primary variable: Degree of contrast enhancement; Border delineation; Internal morphology.
研究概览
简要总结
The purpose of the study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the body/extremities regions. The results of the MRI with gadobutrol injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with Magnevist.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Diagnostic
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Is at least 20 years of age
- •Is referred for a contrast-enhanced MRI of the body/extremities based on current clinical symptoms or results of a previous imaging procedure
- •Is willing to undergo the routine contrast-enhanced MRI examinations
- •Is willing and able to complete all study procedures specified in the protocol
- •Subject is male, or is female not of childbearing potential, or is female of childbearing potential who is using any medically accepted means of contraception and has a negative urine pregnancy test prior to the administration of gadobutrol or Magnevist
排除标准
- •Is a female subject who is pregnant or nursing
- •Has received any investigational product or has participated in any other clinical trial within 2 weeks prior to enrolling in this study
- •Has been previously enrolled in this study or any other study using gadobutrol
- •Has any contraindication to the MRI examinations or the use of Gd-containing contrast agents
- •Has a history of severe allergic or anaphylactoid reaction to any allergen including drugs and contrast agents
- •Has received any contrast agent within 24 hours prior to the study MRI
- •Has a glomerular filtration rate value <30 mL/min/1.73m2 derived from a serum creatinine result within 4 weeks prior to study enrollment
- •Is considered clinically unstable or his/her clinical course during the study period is unpredictable (eg, due to previous surgery, acute renal failure)
- •Has severe cardiovascular disease (eg, acute myocardial infarction (<14 days), unstable angina, congestive heart failure New York Heart Association class IV) or acute stroke (<48 hours)
- •Patients with acute renal insufficiency of any severity due to hepato-renal syndrome or in the perioperative liver transplantation period
- •Has any contraindication to Magnevist according to the package insert
研究组 & 干预措施
Arm 1
Experimental
干预措施: Gadobutrol (Gadovist, BAY86-4875) (Drug)
Arm 2
Active Comparator
干预措施: Gadopentetate Dimeglumine (Magnevist, BAY86-4882) (Drug)
结局指标
主要结局
The total score of the following 3 visualization parameters is used for primary variable: Degree of contrast enhancement; Border delineation; Internal morphology.
时间窗: At Day 0
次要结局
- Sensitivity and specificity for the detection of malignant lesions(At Day 0)
- Exact match of the MR diagnosis with the final clinical diagnosis based on medical records up until 3 months after the scan(At Day 0)
- Confidence in diagnosis(At Day 0)
研究者
相似试验
已完成
2 期
Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)Brain DiseasesSpinal Cord DiseasesNCT00862459Bayer237
招募中
不适用
A Trail of Sperstent® Used for Residual Lesions of Femoropopliteal ArteriesStenosisDissectionPeripheral Arterial DiseaseNCT06539689FrontAce Scientific Co., Ltd240
招募中
不适用
Efficacy and Safety of Sirolimus-Coated Spiral Balloon for Coronary Bifurcation LesionsCoronary Bifurcation LesionNCT06618248Dongguan TT Medical280
终止
1 期
Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic AstigmatismHyperopic AstigmatismHyperopiaNCT01893359Glaukos Corporation2
已完成
不适用
Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AMNon-infected Diabetic Foot UlcerDiabetic WoundNon-ischemic Diabetic Foot UlcerDiabetic FootDiabetic Foot UlcerNCT06565156BioStem Technologies72